



BIOTECHNOLOGY ANALYST

DO KIM

Do joined BMO Capital Markets Equity Research in November 2015 as a biotech analyst. For the past five years, Do was a biotech analyst with Nomura Securities, and Piper Jaffray. Do has over 10 years of experience covering the biotech industry.

Do earned an MBA, finance and economics from Columbia University-Columbia Business School, and a B.A. biology from the Johns Hopkins University. Do is a CFA charterholder.

3 Times Square
29th Floor
New York, NY 10036

Tel: (212) 885-4091
Fax: (212) 885-4060
do.kim@bmo.com

COVERAGE LIST

Affimed N.V. (AFMD-NSDQ)
Akcea Therapeutics (AKCA-NSDQ)
Alnylam Pharmaceuticals (ALNY-NSDQ)
Amgen (AMGN-NSDQ)
BioXcel Therapeutics (BTAI-NSDQ)
Constellation Pharmaceuticals (CNST-NSDQ)
Fate Therapeutics (FATE-NSDQ)
Halozyne Therapeutics (HALO-NSDQ)
Ionis Pharmaceuticals (IONS-OTC)
Morphic Therapeutic (MORF-NSDQ)
ObsEva (OBSV-NSDQ)
Rapt Therapeutics (RAPT-NSDQ)
Replimune Group (REPL-NSDQ)
Retrophin (RTRX-NSDQ)
Rigel Pharmaceuticals (RIGL-NSDQ)
Scholar Rock (SRRK-NSDQ)
Schrödinger (SDGR-NSDQ)
TCR2 Therapeutics (TCRR-NSDQ)
VBI Vaccines (VBIV-NSDQ)
Vertex Pharmaceuticals (VRTX-OTC)